- Raised $125M Public Offering, Mar 2025
- Raised $30M Public Offering, Sep 2025
- Raised $25M Public Offering, Sep 2024
About
MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics for non-surgical tissue repair. Its solutions selectively remove non-viable hazardous tissue while preserving healthy tissue, offering a safer and more effective alternative to traditional methods. With robust in-house research, development, and manufacturing capabilities, the company produces and commercializes cutting-edge biologics for wound and burn care that exceed existing standards of care, improve patient outcomes, and reduce healthcare costs by eliminating the need for surgical interventions. MediWound’s flagship product, NexoBrid, is an FDA, EMA and PMDA approved orphan designated biologic, currently in use worldwide for treating severe burns. Building on its proprietary enzymatic technology, MediWound is advancing EscharEx, a promising Phase III pipeline drug for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
Funding history · 14 rounds · $407.5M total
Offices
Q&A
- What is MediWound's primary focus?
- MediWound is a biopharmaceutical company specializing in developing and commercializing enzymatic therapies for non-surgical tissue repair, particularly for wound and burn care.
- When was MediWound founded and where is its headquarters located?
- MediWound was founded in January 2000 and is headquartered in Yavne, Israel.
- What is MediWound's flagship product?
- MediWound's flagship product is NexoBrid, an FDA, EMA, and PMDA-approved orphan-designated biologic used worldwide for treating severe burns.
- What is MediWound's current pipeline drug?
- MediWound is advancing EscharEx, a Phase III pipeline drug for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
- How much funding has MediWound raised in total?
- MediWound has raised a total of $405,473,265.61 through various funding rounds.
- When was MediWound's most recent funding round and what type was it?
- MediWound's most recent funding round was a Public Offering in November 2026, raising $15,000,000.
- Who are the founders of MediWound?
- The founders of MediWound are Lior Rosenberg and Marian Gorecki.
- Who is the current CEO of MediWound?
- Ofer Gonen is the Chief Executive Officer of MediWound.
Team · 17
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | mediwound.com |
|---|---|
| linkedin.com/company/1644054 | |
| Wikidata | wikidata.org/wiki/Q43896231 |
Identifiers & details
| Legal name | MediWound Ltd. |
|---|---|
| Founded | 2000-1 |
| Employees (exact) | 121 |
| Wikidata QID | Q43896231 |
Radar intelligence
Patents
| EPO | 14 |
|---|
Publications (Crossref)
| Works | 5 |
|---|
Web history (Wayback)
| Domain | mediwound.com |
|---|
Wikidata
| QID | Q43896231 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 512894940 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2000-01-27 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2022 |
| Active charges / liens | 0 |
| Registry events | 1 — charge (1) |
| Registered address | הירקון 42 יבנה |
Recent registry events
| Date | Event |
|---|---|
| 2026-08-12 | עדכון שעבוד |